Live Breaking News & Updates on ரேச்சல் யேட்ஸ்|Page 4

Learn more about Acute Myeloid Leukemia and ONUREG (CNW Group/Bristol Myers Squibb Canada Co.)
AML is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure, and is the most common form of acute leukemia in adults, accounting for approximately 80 per cent of adult cases.
2,3,4 An estimated 40-60 per cent of patients aged 60 years and older and 60-80 per cent of patients under 60 years old will obtain complete remission through induction chemotherapy (IC); however, 50 per cent will relapse within a year.
5,6 Once a relapse occurs, long-term survival averages at six months.
7 In 2015, an estimated 1,235 Canadians were diagnosed with AML and the overall incidence rate in Canada is 3.46/100,000 people. ....

Alannah Nugent , Andre Schuh , Rachel Yates , Garzon Rj Clin , Bristol Myers Squibb , Al Reba , Bristol Myers Squibb Canada Co , Princess Margaret Cancer Centre , Public Health , Bristol Myers Squibb Company , Leukemia Lymphoma Society Of Canada , Health Canada , Corporate Affairs , General Manager , Myers Squibb Canada , Myers Squibb , Product Monograph , Clin Med , Lymphoma Society , Acute Myeloid , Accessed December , Bristol Myers Squibb Canada , Account Executive , Health Care Amp Hospitals , Medical Pharmaceuticals , International Medical Approval ,